Juvenile Idiopathic Arthritis: The Childhood Illness Nobody Talks About

In 2017 my son Thomas collapsed. What followed was the sort of week that reorganises a family permanently. By the time the diagnosis came, the inflammation had reached forty-seven joints. Forty-seven. I remember the number being said aloud and not being able to make it mean anything, because arthritis was a word I associated with elderly relatives and stiff mornings, not with a child who had been running about a fortnight earlier.

That misunderstanding is the whole problem, and it is nearly universal. Almost everybody believes arthritis is a disease of old age caused by wear and tear. Juvenile idiopathic arthritis is not that at all. It is an autoimmune condition in which a child's immune system attacks the lining of their own joints. It has nothing to do with use or age. It is the most common rheumatic disease in childhood, affecting roughly one child in every thousand in the United Kingdom — around fifteen thousand children and young people at any one time. That is more children than are affected by cystic fibrosis, and yet almost nobody could name it.

Idiopathic means we do not know the cause. That single word carries an enormous amount of frustration for families, because the first question every parent asks is why, and the honest answer remains that nobody knows. There are several subtypes. Oligoarticular affects four joints or fewer. Polyarticular affects five or more. Systemic-onset — the form Thomas has — is the most severe. It does not confine itself to joints. It brings spiking fevers, rash and inflammation that can reach internal organs: the heart, the lungs, the liver and spleen. It can trigger a life-threatening complication called macrophage activation syndrome, in which the immune system effectively overwhelms the body. It is the subtype with the hardest course, the hardest treatment and the worst outcomes, and of course it is the one we got.

The symptoms are easy to dismiss, which is precisely why diagnosis is so often delayed. A child who limps in the morning and seems fine by lunchtime. A knee that is warm and swollen and gets blamed on football. Tiredness that is put down to a growth spurt. Reluctance to walk that looks like reluctance to go to school. Parents are frequently told to wait and see, sometimes for months, and in a disease where early aggressive treatment substantially improves the outcome, those months matter enormously.

The complication almost nobody outside the field knows about is the eyes. JIA can cause uveitis, an inflammation inside the eye that is typically completely painless and produces no visible symptom until damage is already done. Untreated, it causes cataracts, glaucoma and permanent sight loss. Children with JIA require regular ophthalmology screening for years, sometimes long after the joints have settled. When people ask me what single fact I would want every parent and every general practitioner to know, it is that one.

Treatment has genuinely improved. Non-steroidal anti-inflammatories, steroid joint injections, methotrexate, and the biologic drugs that target specific parts of the immune response have transformed what is achievable. But these are serious drugs with serious demands, and in our case they go further still. Thomas is on biological trial drugs — therapies at the frontier of what medicine currently offers this disease. They carry real risks. Among them, printed in black and white in the literature you sign before the first dose, is an increased risk of certain cancers. You read that sentence as a parent and then you sign the form anyway, because the alternative is watching the disease take your child apart. The constant, low-grade terror that lives alongside that decision is hard to describe to anyone who has not carried it. Every unexplained symptom, every routine blood result, every scan is weighed against a word you never wanted in your family's vocabulary.

Here is the other thing people get wrong, and it matters. This is not a childhood illness that ends. The name is a historical accident, not a prognosis. A young person with JIA does not lose the disease on their eighteenth birthday, and the diagnosis does not change its name when they become an adult. For a large proportion of patients — and particularly for those with the systemic form — it continues into adult life, sometimes for life. The word juvenile describes when it began, not when it finishes. Yet the entire system is built as if it were a phase: paediatric teams, paediatric wards, paediatric funding, and then a cliff edge at eighteen called transition, which too many young people fall straight through, landing in adult services that see far fewer of these patients and understand them less well.

The standard of care is also not a standard at all. It varies enormously across the United Kingdom and across the globe. We were lucky. Living in Kent, we were referred to Great Ormond Street children's hospital — one of the finest paediatric rheumatology centres in the world, with the specialists, the research access and the trial programmes that a case like Thomas's needs. A great many families do not get that luxury. Their postcode hands them a general paediatric department with no rheumatologist, months of waiting, and a long journey to the nearest centre that can actually help. In parts of the developing world the disease is barely diagnosed at all, and the biologic drugs that are keeping my son on his feet are simply unavailable. Two children with the same diagnosis can have entirely different futures depending on where they happen to be born.

The parts that are never counted are the ones that grind families down. The hospital appointments that eat school attendance until someone sends a letter about it. The blood tests every few weeks. The teacher who does not understand why a child cannot carry a bag today but managed it on Tuesday, because that is exactly how this disease behaves. The friends who drift because you cancelled three times. The fatigue, which is not tiredness and is not laziness and is not, in my experience, taken remotely seriously enough. And beneath all of it, for the parent of a child on powerful immune-suppressing trial medication, a level of background worry that never fully switches off. It is horrific, and it is ordinary life for thousands of families.

Then there is the funding. Research spending on childhood rheumatic disease is a fraction of what goes to other paediatric conditions with comparable or lower prevalence. Paediatric rheumatology in Britain is a small speciality with real workforce shortages. Much of what is prescribed to children was developed and trialled in adults. Public awareness, which drives charitable funding, barely exists — because the disease's own name tells people something untrue about it.

What would help is not complicated. Recognition that children get arthritis, taught properly in primary care so that a limping child with a swollen joint is referred rather than reviewed in six weeks. Equitable access to the specialist centres, so that Great Ormond Street-level care is a right rather than a postcode prize. Universal, reliable eye screening. Research funding proportionate to the number of children affected. And an adult care system that understands that juvenile arthritis grows up.

Thomas has lived with this since 2017. He has handled it with considerably more grace than I would have at his age. I write about it because in the years since that first week I have met a great many families going through the same thing who all said some version of the same sentence: we had never heard of it either. That is a solvable problem, and it starts with saying the words out loud. Children get arthritis. It does not necessarily end when childhood does. And the sooner it is recognised and properly treated, wherever in the world a child happens to live, the better those children do.